Britain and America have reached a important commercial pact that will guarantee zero tariffs on British medicine shipments going into the US market.
Agreement Details of the Deal
As part of the deal, the UK has committed to increase expenditure on drugs through the National Health Service (NHS). This pledge secures that tariffs on these crucial products will be held at zero for a period of the next three years.
This deal is in response to previous warnings to hike tariffs on patented pharmaceutical imports, with increases floated as high as double the cost.
"This arrangement between the UK reinforces the worldwide climate for cutting-edge drugs and brings much-needed equity to American-British drug exports," a release declared.
Commercial Importance
Pharmaceuticals constitute one of the UK's largest export categories to the America, which is easily the primary market for large companies like GSK and AstraZeneca.
Statistics indicate that in the one-year period prior to September, the UK shipped pharmaceutical products worth £11.1bn to the US. This amount accounted for 17.4% of all goods exports in that period.
"This guarantee safeguards jobs, boosts investment and facilitates the UK to establish itself as a global hub for medical research," the Business and Trade Secretary remarked.
Specific NHS Changes
The deal includes several notable pledges from the UK:
- Price Threshold Increase: The UK will lift the price threshold at which it judges new treatments to be too expensive by 25%.
- Boosted Medicine Funding: There is a target to raise total public funding on drugs from 0.3% of the national economy to 0.6% over the coming ten years.
- Rebate Cap: The amount pharmaceutical firms must pay back to the NHS to prevent overspending will be capped at fifteen percent. Previously, repayments topped 20%.
Broader Context
The deal takes place against a ongoing dispute between the drug companies and the UK government over medicine costs and approval rates.
The disagreement were exacerbated by claims that American customers were charged significantly more for the identical medicines than patients in the UK and Europe.
Recently, several major drug company projects in the UK have been halted or scrapped, while substantial investments have been pledged toward US facilities.
The Science Minister stated that the NHS needed to invest a greater share on medicines, noting that its spending on drugs had shrunk as a percentage of its resources over the previous ten-year period.
